Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that patients with alopecia areata treated with ritlecitinib in a real-life setting had a higher rate of positive response on the Severity of Alopecia Tool score compared to those in the ALLEGRO trial.

This study found that the optimized AR antagonist compound 39 showed potent hair growth activity with improved safety in mice, suggesting potential for better topical treatments for androgenetic alopecia.

This study found that elevated tissue RBP4 levels correlate with disease severity in alopecia areata and decrease after effective baricitinib treatment, while the rs3758539 polymorphism is linked to disease susceptibility but not to treatment response.

This study suggests that RORα, RORβ, and RORγ mRNA expression in cashmere goat skin is related to different stages of hair follicle development, indicating a possible role in cycled cashmere growth.

This review examines the patent literature on AKR1C3 inhibitors and suggests that although numerous potent inhibitors exist, further preclinical optimization is necessary before assessing their therapeutic potential in human diseases.

This review discusses the clinical applications and adverse effects of 5-alpha reductase inhibitors for treating benign prostatic hyperplasia and androgenic alopecia, noting controversies around their implications for other diseases, without reporting new results.

In this study, the researchers reported that the optimized compound 39 demonstrated potent AR antagonism and favorable pharmacokinetics in a hair-growth mouse model, achieving similar efficacy to pyrilutamide with faster onset and preserved safety, offering promise for next-generation topical AR antagonist development.

Off-label drug use can be risky and requires careful consideration to ensure patient safety.

In this study, researchers observed that red and red-orange LED light therapy stimulates nitric oxide production and decreases dihydrotestosterone synthesis in cell models, suggesting a potential mechanism for using light therapy to treat androgenetic alopecia.

This study identified compounds from Laportea bulbifera with potential inhibitory effects on human steroid 5α-reductase 2, suggesting their application in treating benign prostatic hyperplasia.

This study found that oregonin isolated from Alnus japonica exhibits strong antioxidant activity and may promote hair growth, suggesting its potential use in cosmetic products.

This study details a case of a 20-year-old woman with APECED syndrome and alopecia areata who experienced complete scalp hair regrowth and improved quality of life after nine months of ruxolitinib treatment, highlighting the drug's effectiveness for severe AA linked to AIRE gene mutation.

This study found that among adolescents with alopecia areata and significant hair loss, treatment with ritlecitinib resulted in greater hair regrowth and self-reported improvement compared to placebo over 48 weeks, with common side effects including headache, acne, and nasopharyngitis.

In this computational study, researchers identified six phytochemicals, including Jamogenin, that effectively bind to the enzyme 5-AR, potentially promoting hair growth, and found that encapsulating Jamogenin in lipid nanoparticles enhances its stability.

In this study, dihydroartemisinin reduced prostate enlargement and related markers in a rat model of benign prostatic hyperplasia, suggesting its potential as a therapeutic agent.

This review analyzed clinical trials and guidelines on 5-α-reductase inhibitors (5-ARIs) and found these drugs significantly improve urinary symptoms in BPH and stabilize hair loss in androgenic alopecia, but may cause sexual dysfunction and gynecomastia.

This abstract does not provide any specific results or findings but describes male androgenic alopecia as a progressive and psychologically distressing hair-loss disorder involving hair follicle miniaturization.

This article explores the interactions between retinoids and the immune system but reports no new clinical results related to their role in hair cycle control.

This study reports that using 5-alpha reductase inhibitors is associated with a 31% increased risk of depression, highlighting that the choice of comparator group significantly affects study results.

In this study, researchers developed and tested a gel containing apocynin-loaded nanoparticles that showed promising results in treating rheumatoid arthritis in rats, suggesting potential for novel topical treatments in inflammatory conditions.

This study found that long-term use of 5α-reductase inhibitors is associated with improved overall survival in men with renal cell carcinoma, particularly those with low comorbidity not receiving surgery or systemic therapy, suggesting a potential role for androgen modulation in disease management.

This study found that 4-(4-Phenoxybenzoyl)benzoic acid derivatives may act as antioxidants by scavenging certain reactive oxygen species but exhibit prooxidant behavior under specific conditions.

This study found that arginine deficiency in androgenetic alopecia patients is linked to increased oxidative stress and impaired hair follicle regeneration, with targeted arginine supplementation showing promise as a therapeutic strategy.

This study found that arctiin, a compound from Arctium lappa, demonstrated protective effects against oxidative stress-induced dysfunction in human hair dermal papilla cells, suggesting potential therapeutic use for alopecia.

This case report details a woman with postural orthostatic tachycardia syndrome who experienced notable dermatological symptoms, including evanescent hyperemia, which improved with the use of an oral angiotensin II type 1 receptor antagonist.

This study found that taxifolin glycosides isolated from Rhododendron mucronulatum showed promise for developing treatments for male pattern hair loss by inhibiting DHT production and enhancing hair growth-promoting factors.

This review discusses the repurposing of auranofin for oncological and non-oncological uses and highlights its early-stage clinical trial findings, suggesting further exploration of its therapeutic potential.

This study observed that most patients with alopecia areata experienced sustained scalp hair regrowth after 48 weeks of ritlecitinib treatment, with safety consistent with prior findings.

This study identified ALDH1A1 as a regulator of melanogenesis and suggests its inhibition, through agents like cyanamide, may be a promising therapeutic approach for treating hyperpigmentation disorders such as melasma.

In this study, daily treatment with angiotensin (1-7) significantly reduced disease severity in a mouse model of Systemic Lupus Erythematosus, suggesting potential for Mas agonists in future therapies.